Esperion settlement prevents generic NEXLETOL and NEXLIZET filing until 2040
Esperion (ESPR) reached a settlement agreement with a sixth ANDA filer that the filer will not market a generic version of NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid & ezetimibe) prior to April 19, 2040.